The June 2026 issue examines evolving strategies in heart failure-related cardiogenic shock, mechanical circulatory support, guideline-directed medical therapy, and palliative cardiology.
WASHINGTON, DC (June 9, 2026) – Heart failure-related cardiogenic shock has now surpassed acute myocardial infarction-related cardiogenic shock as the leading cause of cardiogenic shock, according to articles featured in the June 2026 issue of the Journal of Cardiac Failure (JCF).
The issue brings together new perspectives on the evolving management of heart failure-related cardiogenic shock (HF-CS), including the growing role of Impella 5.5 support, the challenges of implementing guideline-directed medical therapy during shock, and the integration of palliative care into advanced heart failure management.
Among the featured articles is Impella 5.5 Support in HF-CS: Setting the Stage to SURPASS Our Limitations, which explores the unique clinical and physiologic challenges associated with HF-related cardiogenic shock and examines how delays in recognition and hemodynamic assessment may contribute to poor outcomes. The article discusses how management pathways for HF-CS differ substantially from those traditionally established for acute myocardial infarction-related shock.
The issue also includes Fortune or Folly: Medical Therapy in Cardiogenic Shock on Impella Support, which examines the growing clinical interest in initiating or maintaining guideline-directed medical therapy (GDMT) during cardiogenic shock supported with mechanical circulatory support. The article addresses the tension between the known long-term benefits of neurohormonal blockade in chronic heart failure and the hemodynamic instability that often limits their use during shock states.
Additionally, the June issue features an editorial, Redefining Care for Advanced Heart Failure: The HeartPal Program and the Future of Palliative Cardiology, which focuses on the expanding role of palliative care in advanced heart failure. The article reviews evidence demonstrating improvements in symptom burden, quality of life, and hospital readmissions when palliative care is integrated into cardiovascular care earlier in the disease course.
View the full issue online. For interviews with authors, please contact Laura Poko at [email protected].
About the Journal of Cardiac Failure
The Journal of Cardiac Failure (JCF) publishes the highest quality science in the field of heart failure with a focus on diversity, equity, and inclusion, mentorship, multidisciplinary partnerships, and patient-centeredness. Published papers span original investigator-initiated work to state-of-the-art reviews, guidelines and scientific statements, expert perspectives, early career and trainee spotlight pieces, patient and patient-partner narratives. JCF also emphasizes the power of language and prioritizes innovative approaches to dissemination of published work to reach and impact the broader heart failure community.
About the Heart Failure Society of America
The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org.
Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected]